این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
یکشنبه 8 شهریور 1405
International Journal of Hematology-Oncology and Stem Cell Research
، جلد ۱۱، شماره ۴، صفحات ۲۸۶-۲۹۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
چکیده انگلیسی مقاله
Background: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected. Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95% confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95% CI: 0.43-6.81). Conclusion : This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin- induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
آدم f binder | adam f binder
icahn school of medicine at mount sinai 1 gustave l levy place new york, ny 10029
سونیا رای | sonia rai
icahn school of medicine at mount sinai 1 gustave l levy place new york, ny 10029
امیر steinberg | amir steinberg
نشانی اینترنتی
http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/776
فایل مقاله
اشکال در دسترسی به فایل - ./files/site1/rds_journals/78/article-78-429910.pdf
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
Original Article(s)
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات